Medtronic plc (MDT) is scheduled to report first-quarter fiscal 2025 results on Aug 20, before the opening bell.In the last reported quarter, the company’s adjusted earnings of $1.46 exceeded the Zacks Consensus Estimate by 0.69%. Medtronic beat estimates in each of the trailing four quarters, the average surprise being 4.48%.The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $7.90 billion, suggesting growth of 2.5% year over year. The consensus estimate for first-quarter earnings i ...

JHVEPhoto Medtronic (NYSE:MDT) continues to tread water as the broader market advances. The stock is up just 4% over the past 12 months, significantly underperforming the iShares U.S. Medical Devices ETF (IHI) which is higher by 10%. The Health Care Sector ETF (XLV) has returned better than 15% while the S&P 500 has beaten them all with a 28% performance from year-ago levels. I reiterate a buy rating on MDT, though. I see the stock as still undervalued today ahead of its Q1 2025 earnings report due out ...

JHVEPhotoInvestment thesis My initial bullish thesis about Medtronic (NYSE:MDT) aged somewhat good as the stock delivered a total 1.9% return since mid-February. As I underlined in my initial thesis, MDT is a good option for investors seeking low-volatility stock with solid dividend growth. The company reports its fiscal Q1 earnings soon, on August 20. Today I want to update my thesis and explain why I believe there are robust reasons to remain moderately bullish about MDT. Moreover, the valuation still ...

The office building of Medtronic Inc., an American medical technology company, is being pictured in ... [+] Shanghai, China, on July 23, 2024. (Photo by Costfoto/NurPhoto via Getty Images)NurPhoto via Getty ImagesMedtronic (NYSE: MDT) is scheduled to report its fiscal 2025 first-quarter results on Tuesday, August 20 (fiscal year ends in April). We expect Medtronic stock to trade higher post-Q1 results announcement, with its revenues and earnings expected to be slightly above the street estimates. The compan ...

GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividen ...

Medtronic (MDT) recently announced two major developments within its diabetes care business. The company received FDA approval for its Simplera continuous glucose monitor (CGM), which marks a significant step forward in diabetes management.Along with the FDA approval, Medtronic announced a global partnership with another MedTech stalwart, Abbott (ABT) . Considering the fact that the global diabetes care market has shown remarkable growth over the past few years, this partnership is expected to be strategica ...

In its upcoming report, Medtronic (MDT) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $7.9 billion, representing a year-over-year increase of 2.5%.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals its earni ...

报告行业投资评级 报告将Medtronic PLC的评级从Sell上调至Neutral,主要原因是对Diabetes业务的可持续性增长有了更高的确信度。[2] 报告的核心观点 1) Medtronic的Diabetes业务有望保持约4%的销售增长,这将抵消其他业务的下滑。[2][9][10] 2) Medtronic与Abbott的Libre CGM合作以及780G产品的正面反馈,增强了Diabetes业务的可持续性。[4][10] 3) 预计Medtronic的Diabetes销售在2026财年前后将实现双位数增长,高于市场预期。[17][18][19][20] 分部总结 Diabetes业务 1) Diabetes业务占Medtronic总销售不到10%,但是是其最高增长的领域之一,对整体销售增长至关重要。[2] 2) Medtronic与Abbott的Libre CGM合作以及780G产品的正面反馈,增强了Diabetes业务的可持续性。[4][10] 3) 预计Medtronic的Diabetes销售在2026财年前后将实现双位数增长,高于市场预期。[17][18][19][20] 其他业务 1) 预计Medtronic的其他业务可能会出现一些下滑,但Diabetes业务的增长可以抵消这一影响。[2] 估值 1) 我们认为Medtronic的估值可以重新评估,与其历史5年平均水平以及同行业可比公司的估值水平更为接近。[22][23][24]

Medtronic (MDT) closed the most recent trading day at $82.27, moving +1.33% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1.69% for the day. At the same time, the Dow added 1.04%, and the tech-heavy Nasdaq gained 2.43%.Shares of the medical device company have appreciated by 5.33% over the course of the past month, outperforming the Medical sector's loss of 0.57% and the S&P 500's loss of 4.78%.The investment community will be closely monitoring the perfo ...

GALWAY, Ireland, Aug. 12, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2025 on Tuesday, August 20, 2024. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's first quarter of fiscal year 2025, which ended on Friday ...